Abbott Laboratories · ABT
$10.9B
$11.5B
$11.9B
$11.3B
$10.4B
$10.1B
$9.7B
$10.0B
$10.1B
$10.2B
$10.0B
$10.4B
$10.6B
$11.0B
$10.4B
$11.1B
$11.4B
$11.5B
$11.2B
$12.6B
20-quarter listed-company comparison
Medical Devices Stocks
Medical Devices: Abbott Laboratories owns the largest revenue base; Establishment Labs Holdings Inc. has the fastest current growth.
01 · the industry itself · before any single company
How has Medical Devices moved against S&P 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 2% ahead of S&P 500. Earnings across its companies grew 21% on average over the last four reported quarters. It has been ahead of S&P 500 on a rolling three-month view for 7 weeks running.
BREAKING OUT · ahead 7w~Moving with the index39 of 71 companies ahead of S&P 500 by 5% or more over three months6 are 20% or more behind over a year while earnings grew 20% or more
RS ↑7w · 37/71 >200d (−1) · 39/71 lead (+9) · EPS 42/70↑
Medical Devices, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Medical Devices, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Medical Devices, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 71 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
02 · sector relative strength, before individual stocks
Is Medical Devices outperforming S&P 500?
Medical Devices has outperformed S&P 500 by 12.5% over the last 52 weeks. Over 13 weeks the gap is a lead of 17.9%. 13 of 29 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Butterfly Network, Inc. is the strongest against the sector itself at +88.6%.
+17.9%Sector vs S&P 500 · 13 weeks
+12.5%Sector vs S&P 500 · 52 weeks
13/29Stocks leading S&P 500
11/29Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Medical Devices has outperformed S&P 500 by 12.5% over 52 weeks and 17.9% over 13 weeks. 13 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 11 of 29 beat the sector itself. Abbott Laboratories leads with revenue of $46,585 million, based on 15 of 30 comparable companies through Jun 2026.
Companies
30
complete canonical membership
Combined market value
$788.7B
Abbott Laboratories
Revenue growing
14/15
positive TTM year-on-year growth
Beating S&P 500
13/29
positive Mansfield relative strength
Comparing 5 of 30
03 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
DexCom, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 57.8% evidence confidence.
Haemonetics Corporation looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
UFP Technologies, Inc. has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1DexCom, Inc.DXCM | 66.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 22.9/35 Revenue — · PAT — · OPM change 8.5 pp 45% evidence | 16.8/25 ROCE 7.8% · OPM 21.4% 76% evidence | 9.9/20 P/E 26.6× · PEG — 15% evidence | 16.5/20 RS sector 6.5% · RS bench 12.9% · 1Y 10.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 16.8 + 9.9 + 16.5 = 66.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Globus Medical, Inc.GMED | 60.3/100Mixed-positive evidence81% evidence | ASLEEP | 25.6/35 Revenue 23.5% · PAT 100% · OPM change 3.6 pp 83% evidence | 14.8/25 ROCE 3.2% · OPM 19.8% 76% evidence | 15.2/20 P/E 20× · PEG 0.85 65% evidence | 4.7/20 RS sector -13.1% · RS bench -8.3% · 1Y 39%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.6 + 14.8 + 15.2 + 4.7 = 60.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -13.1% and the one-year return is 39%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3LivaNova PLCLIVN | 57.8/100Mixed-positive evidence64% evidence | BREAKING OUT | 24.7/35 Revenue 12.4% · PAT — · OPM change 109.8 pp 62% evidence | 11.1/25 ROCE 2.3% · OPM 11.4% 76% evidence | 9.5/20 P/E 32.6× · PEG — 15% evidence | 12.5/20 RS sector 11.8% · RS bench 18.6% · 1Y 74.7%9 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 11.1 + 9.5 + 12.5 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4UFP Technologies, Inc.UFPT | 56.3/100Mixed-positive evidence81% evidence | BREAKING OUT | 15.7/35 Revenue 11.3% · PAT 7.9% · OPM change -0.4 pp 83% evidence | 15.2/25 ROCE 4% · OPM 15.2% 76% evidence | 6.5/20 P/E 22× · PEG 2.9 65% evidence | 18.9/20 RS sector 27.1% · RS bench 34.5% · 1Y 62.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 15.2 + 6.5 + 18.9 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 34.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5STERIS plcSTE | 56.1/100Mixed-positive evidence81% evidence | TURNING | 22.3/35 Revenue 8.9% · PAT 27.4% · OPM change 5.3 pp 83% evidence | 14.8/25 ROCE 3.4% · OPM 19.9% 76% evidence | 12.8/20 P/E 27.9× · PEG 1 65% evidence | 6.2/20 RS sector -16.8% · RS bench -12% · 1Y -4.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 14.8 + 12.8 + 6.2 = 56.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Edwards Lifesciences CorporationEW | 55.6/100Thin evidence · provisional58% evidence | TURNING | 22.1/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 17.9/25 ROCE 8.5% · OPM 29% 76% evidence | 9.0/20 P/E 52× · PEG — 15% evidence | 6.6/20 RS sector -8.3% · RS bench -2.8% · 1Y 14.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 17.9 + 9 + 6.6 = 55.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Establishment Labs Holdings Inc.ESTA | 52.5/100Mixed-positive evidence61% evidence | BREAKING OUT | 25.0/35 Revenue 35.3% · PAT — · OPM change 30.1 pp 62% evidence | 3.6/25 ROCE -2.4% · OPM -10.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.9/20 RS sector 22.8% · RS bench 29.8% · 1Y 171.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 3.6 + 10 + 13.9 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Butterfly Network, Inc.BFLY | 52.5/100Thin evidence · provisional55% evidence | LEADER | 19.4/35 Revenue — · PAT — · OPM change 34.7 pp 45% evidence | 3.1/25 ROCE -5.5% · OPM -52.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 88.6% · RS bench 99.8% · 1Y 562.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 3.1 + 10 + 20 = 52.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Stryker CorporationSYK | 52.3/100Thin evidence · provisional58% evidence | TURNING | 19.5/35 Revenue — · PAT — · OPM change 1.2 pp 45% evidence | 15.6/25 ROCE 4.1% · OPM 15.5% 76% evidence | 9.4/20 P/E 32.6× · PEG — 15% evidence | 7.8/20 RS sector -18.8% · RS bench -14% · 1Y -11%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 15.6 + 9.4 + 7.8 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Boston Scientific CorporationBSX | 52.1/100Thin evidence · provisional58% evidence | BASING | 22.2/35 Revenue — · PAT — · OPM change 1.4 pp 45% evidence | 17.0/25 ROCE 6.5% · OPM 21.2% 76% evidence | 11.2/20 P/E 17.3× · PEG — 15% evidence | 1.7/20 RS sector -46.8% · RS bench -43.8% · 1Y -52.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 17 + 11.2 + 1.7 = 52.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Integer Holdings CorporationITGR | 51.9/100Thin evidence · provisional58% evidence | TURNING | 13.3/35 Revenue — · PAT — · OPM change -5.3 pp 45% evidence | 10.1/25 ROCE 1% · OPM 7.2% 76% evidence | 10.8/20 P/E 21.6× · PEG — 15% evidence | 17.7/20 RS sector 18.1% · RS bench 25.5% · 1Y 17.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 10.1 + 10.8 + 17.7 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Zimmer Biomet Holdings, Inc.ZBH | 48.7/100Mixed-negative evidence81% evidence | TURNING | 16.9/35 Revenue 9.2% · PAT -16.9% · OPM change 2.6 pp 83% evidence | 12.1/25 ROCE 1.9% · OPM 17.9% 76% evidence | 12.3/20 P/E 23.5× · PEG 1.09 65% evidence | 7.4/20 RS sector -13.2% · RS bench -8% · 1Y -3.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 12.1 + 12.3 + 7.4 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Glaukos CorporationGKOS | 48.6/100Thin evidence · provisional55% evidence | BREAKING OUT | 18.6/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 4.2/25 ROCE -2% · OPM -13.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.8/20 RS sector 28% · RS bench 35.5% · 1Y 101.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 4.2 + 10 + 15.8 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Insulet CorporationPODD | 47.7/100Mixed-negative evidence71% evidence | TURNING | 19.0/35 Revenue 31.9% · PAT -24.6% · OPM change 0.4 pp 83% evidence | 14.9/25 ROCE 4.6% · OPM 16% 76% evidence | 9.2/20 P/E 48.8× · PEG — 15% evidence | 4.6/20 RS sector -43.2% · RS bench -40% · 1Y -45.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 14.9 + 9.2 + 4.6 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Neogen CorporationNEOG | 46.7/100Thin evidence · provisional58% evidence | TURNING | 18.0/35 Revenue — · PAT — · OPM change -4 pp 45% evidence | 6.3/25 ROCE 0.1% · OPM -1.6% 76% evidence | 8.5/20 P/E 1719× · PEG — 15% evidence | 13.9/20 RS sector 22.2% · RS bench 29.2% · 1Y 132.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 6.3 + 8.5 + 13.9 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16GE HealthCare Technologies Inc.GEHC | 45.4/100Thin evidence · provisional58% evidence | TURNING | 15.3/35 Revenue — · PAT — · OPM change -3.2 pp 45% evidence | 13.4/25 ROCE 2.7% · OPM 10% 76% evidence | 11.4/20 P/E 14.7× · PEG — 15% evidence | 5.3/20 RS sector -18.8% · RS bench -14.2% · 1Y -2.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 13.4 + 11.4 + 5.3 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Haemonetics CorporationHAE | 44.8/100Mixed-negative evidence81% evidence | BREAKING OUT | 5.4/35 Revenue -2.1% · PAT -41.3% · OPM change -28.2 pp 83% evidence | 7.0/25 ROCE -1.2% · OPM -6.6% 76% evidence | 15.1/20 P/E 26.4× · PEG 0.52 65% evidence | 17.3/20 RS sector 10.9% · RS bench 17% · 1Y 58.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 5.4 + 7 + 15.1 + 17.3 = 44.8 · Decision use: Price leads the evidence: RS versus the benchmark is 17%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Koninklijke Philips N.V.PHG | 44.3/100Thin evidence · provisional58% evidence | BASING | 19.4/35 Revenue — · PAT — · OPM change 2.4 pp 45% evidence | 10.9/25 ROCE 3.2% · OPM 6.2% 76% evidence | 11.0/20 P/E 20.5× · PEG — 15% evidence | 3.0/20 RS sector -19.4% · RS bench -14.6% · 1Y -1.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 10.9 + 11 + 3 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Medtronic plcMDT | 43.1/100Mixed-negative evidence85% evidence | TURNING | 18.1/35 Revenue 8.4% · PAT 3.1% · OPM change 3 pp 95% evidence | 14.3/25 ROCE 2.3% · OPM 19.1% 76% evidence | 5.6/20 P/E 22.3× · PEG 3.08 65% evidence | 5.1/20 RS sector -19.6% · RS bench -15% · 1Y -7.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 14.3 + 5.6 + 5.1 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20TransMedics Group, Inc.TMDX | 41.6/100Mixed-negative evidence71% evidence | TURNING | 16.7/35 Revenue 30.1% · PAT 100% · OPM change -11.5 pp 83% evidence | 8.7/25 ROCE 1.3% · OPM 7.6% 76% evidence | 10.5/20 P/E 22.6× · PEG — 15% evidence | 5.7/20 RS sector -37.4% · RS bench -34.1% · 1Y -29.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 8.7 + 10.5 + 5.7 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Axogen, Inc.AXGN | 40.8/100Thin evidence · provisional55% evidence | FADING | 12.2/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence | 5.6/25 ROCE -0.9% · OPM -4.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.0/20 RS sector 25.1% · RS bench 32.6% · 1Y 230.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 5.6 + 10 + 13 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22iRhythm Holdings, Inc.IRTC | 40.3/100Mixed-negative evidence61% evidence | TURNING | 22.9/35 Revenue 27.3% · PAT — · OPM change 12.4 pp 62% evidence | 4.6/25 ROCE -1.9% · OPM -8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -26.9% · RS bench -22.6% · 1Y -19.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 4.6 + 10 + 2.8 = 40.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.9% and the one-year return is -19.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 23Inspire Medical Systems, Inc.INSP | 40.0/100Mixed-negative evidence75% evidence | TURNING | 17.3/35 Revenue 9.1% · PAT 98.5% · OPM change 0.2 pp 83% evidence | 6.1/25 ROCE -0.2% · OPM -0.5% 76% evidence | 12.3/20 P/E 11.5× · PEG 1.35 65% evidence | 4.3/20 RS sector -23.1% · RS bench -19.2% · 1Y -19%1 of 12 weeks ahead 70% evidence |
| Exact sum: 17.3 + 6.1 + 12.3 + 4.3 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24NovoCure LimitedNVCR | 39.4/100Thin evidence · provisional55% evidence | FADING | 16.0/35 Revenue — · PAT — · OPM change -14.3 pp 45% evidence | 3.8/25 ROCE -2% · OPM -38.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.6/20 RS sector 0.9% · RS bench 7.4% · 1Y 46.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 3.8 + 10 + 9.6 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Penumbra, Inc.PEN | 39.0/100Thin evidence · provisional58% evidence | ASLEEP | 14.0/35 Revenue — · PAT — · OPM change -2.2 pp 45% evidence | 11.5/25 ROCE 2.5% · OPM 10.2% 76% evidence | 8.6/20 P/E 134.4× · PEG — 15% evidence | 4.9/20 RS sector -10.6% · RS bench -5.4% · 1Y 34.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 11.5 + 8.6 + 4.9 = 39 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Abbott LaboratoriesABT | 35.2/100Mixed-negative evidence85% evidence | TURNING | 7.9/35 Revenue 8.1% · PAT -61.2% · OPM change -5 pp 95% evidence | 12.8/25 ROCE 2.1% · OPM 13.4% 76% evidence | 7.3/20 P/E 29.4× · PEG 2.31 65% evidence | 7.2/20 RS sector -21% · RS bench -16.4% · 1Y -21.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 12.8 + 7.3 + 7.2 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Bruker CorporationBRKR | 34.5/100Adverse evidence71% evidence | LEADER | 8.0/35 Revenue 0.3% · PAT -112.7% · OPM change -2.8 pp 83% evidence | 9.2/25 ROCE 0.2% · OPM 1.2% 76% evidence | 8.8/20 P/E 79.2× · PEG — 15% evidence | 8.5/20 RS sector -2.2% · RS bench 3.6% · 1Y 65.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 8 + 9.2 + 8.8 + 8.5 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Enovis CorporationENOV | 46.0/100Thin evidence · provisional50% evidence | TURNING | 19.6/35 Revenue — · PAT — · OPM change 9.5 pp 39% evidence | 6.5/25 ROCE 0.2% · OPM 1.1% 76% evidence | 8.9/20 P/E 58.3× · PEG — 15% evidence | 11.0/20 RS sector -2% · RS bench 4% · 1Y 8.5%3 of 12 weeks ahead 70% evidence |
| Exact sum: 19.6 + 6.5 + 8.9 + 11 = 46 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Smith & Nephew plcSNN | 42.9/100Thin evidence · provisional38% evidence | BASING | 17.5/35 Revenue — · PAT — · OPM change — 9% evidence | 12.4/25 ROCE 2.1% · OPM — 46% evidence | 10.3/20 P/E 22.9× · PEG — 15% evidence | 2.7/20 RS sector -23% · RS bench -18.4% · 1Y -15.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 12.4 + 10.3 + 2.7 = 42.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Bio-Rad Laboratories, Inc.BIO-B | 41.8/100Thin evidence · provisional44% evidence | TURNING | 14.8/35 Revenue 1.9% · PAT — · OPM change 1.8 pp 62% evidence | 7.7/25 ROCE 0.4% · OPM 5.8% 76% evidence | 9.3/20 P/E 45.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 4 weeks ahead 0% evidence |
| Exact sum: 14.8 + 7.7 + 9.3 + 10 = 41.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Showing 10 of 30 companies
04 · what price has already done
Market action
Butterfly Network, Inc. has the strongest one-year price move in Medical Devices at +562.4%. It also leads on Mansfield relative strength against the S&P 500 at +99.8%. 13 of 29 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-08-04.
Price and relative strength
Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Medical Devices itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · compare level, then change
Revenue Scale & Growth Durability
Abbott Laboratories has the highest Revenue among the 30 Medical Devices companies compared here, at $46,585 million. Medtronic plc is next at $36,363 million. Establishment Labs Holdings Inc. has the highest Revenue growth at 35.3%, so level and change sit with different companies. 15 of 30 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Abbott Laboratories is the scale leader at $46,585 million, 28.1% ahead of Medtronic plc. Establishment Labs Holdings Inc.'s growth is 35.3% from a $230 million base, with 19 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderAbbott Laboratories · $46,585 million
Gap28.1% versus #2 · Medtronic plc
Persistence8/8 recent comparable periods
Coverage15/30 companies · 559 observations
Investor read: Abbott Laboratories is the scale benchmark; Establishment Labs Holdings Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Abbott Laboratories's growth falls below Establishment Labs Holdings Inc.'s for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
15/30 level · 15/30 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Abbott Laboratories ABT | $12.6B | 13% | Jun 2026 |
| Medtronic plc MDT | $9.8B | 9.9% | Jun 2026 |
| Stryker Corporation SYK | $6.0B | 2.6% | Jun 2026 |
| Boston Scientific Corporation BSX | $5.2B | 12% | Jun 2026 |
| GE HealthCare Technologies Inc. GEHC | $5.1B | 7.4% | Jun 2026 |
| Koninklijke Philips N.V. PHG | $3.9B | -4.7% | Jun 2026 |
| Smith & Nephew plc SNN | $3.2B | 7.4% | Dec 2025 |
| Zimmer Biomet Holdings, Inc. ZBH | $2.1B | 9.3% | Mar 2026 |
| Edwards Lifesciences Corporation EW | $1.6B | 17% | Jun 2026 |
| STERIS plc STE | $1.6B | 7.2% | Mar 2026 |
| DexCom, Inc. DXCM | $1.2B | 15% | Jun 2026 |
| Bruker Corporation BRKR | $823M | 2.8% | Mar 2026 |
| Insulet Corporation PODD | $762M | 34% | Mar 2026 |
| Globus Medical, Inc. GMED | $760M | 27% | Mar 2026 |
| Bio-Rad Laboratories, Inc. BIO-B | $592M | 1.2% | Mar 2026 |
| Enovis Corporation ENOV | $589M | 5.4% | Jun 2026 |
| Integer Holdings Corporation ITGR | $440M | -7.6% | Jun 2026 |
| Penumbra, Inc. PEN | $375M | 16% | Jun 2026 |
| LivaNova PLC LIVN | $362M | 14% | Mar 2026 |
| Haemonetics Corporation HAE | $346M | 4.5% | Mar 2026 |
| Neogen Corporation NEOG | $211M | -4.5% | Jun 2026 |
| Inspire Medical Systems, Inc. INSP | $205M | 2.0% | Mar 2026 |
| iRhythm Holdings, Inc. IRTC | $199M | 25% | Mar 2026 |
| TransMedics Group, Inc. TMDX | $174M | 21% | Mar 2026 |
| NovoCure Limited NVCR | $174M | 12% | Jun 2026 |
| UFP Technologies, Inc. UFPT | $154M | 4.1% | Mar 2026 |
| Glaukos Corporation GKOS | $151M | 41% | Jun 2026 |
| Axogen, Inc. AXGN | $61M | 24% | Jun 2026 |
| Establishment Labs Holdings Inc. ESTA | $60M | 46% | Mar 2026 |
| Butterfly Network, Inc. BFLY | $27M | 29% | Jun 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Boston Scientific Corporation · BSX
$2.9B
$3.1B
$3.0B
$3.2B
$3.2B
$3.2B
$3.4B
$3.6B
$3.5B
$3.7B
$3.9B
$4.1B
$4.2B
$4.6B
$4.7B
$5.1B
$5.1B
$5.3B
$5.2B
—
DexCom, Inc. · DXCM
$650M
$698M
$629M
$696M
$770M
$815M
$742M
$871M
$975M
$1.0B
$921M
$1.0B
$994M
$1.1B
$1.0B
$1.2B
$1.2B
$1.3B
$1.2B
—
Edwards Lifesciences Corporation · EW
$1.3B
$1.3B
$1.3B
$1.4B
$1.3B
$1.3B
$1.5B
$1.3B
$1.2B
$1.3B
$1.3B
$1.4B
$1.4B
$1.4B
$1.4B
$1.5B
$1.6B
$1.6B
$1.6B
—
GE HealthCare Technologies Inc. · GEHC
$4.3B
$4.6B
$4.3B
$4.5B
$4.6B
$4.9B
$4.7B
$4.8B
$4.8B
$5.2B
$4.7B
$4.8B
$4.9B
$5.3B
$4.8B
$5.0B
$5.1B
$5.7B
$5.1B
—
Koninklijke Philips N.V. · PHG
$4.2B
$4.9B
$3.9B
$4.2B
$4.3B
$5.4B
$4.2B
$4.5B
$4.5B
$5.1B
$4.1B
$4.5B
$4.4B
$5.0B
$4.1B
$4.3B
$4.3B
$5.1B
$3.9B
—
Medtronic plc · MDT
$8.0B
$7.8B
$7.8B
$8.1B
$7.4B
$7.6B
$7.7B
$8.5B
$7.7B
$8.0B
$8.1B
$8.6B
$7.9B
$8.4B
$8.3B
$8.9B
$8.6B
$9.0B
$9.0B
$9.8B
Penumbra, Inc. · PEN
$190M
$204M
$204M
$208M
$214M
$221M
$241M
$261M
$271M
$285M
$279M
$299M
$301M
$316M
$324M
$339M
$355M
$385M
$375M
—
Smith & Nephew plc · SNN
$2.6B
$2.6B
—
—
$2.6B
$2.6B
—
—
$2.7B
$2.8B
—
$2.8B
—
$3.0B
—
$3.0B
—
$3.2B
—
—
STERIS plc · STE
$1.2B
$1.2B
$1.2B
$1.2B
$1.2B
$1.2B
$1.4B
$1.2B
$1.2B
$1.3B
$1.4B
$2.6B
$2.7B
$1.4B
$1.5B
$2.8B
$2.9B
$1.5B
$1.6B
—
Stryker Corporation · SYK
$4.2B
$4.7B
$4.3B
$4.5B
$4.5B
$5.2B
$4.8B
$5.0B
$4.9B
$5.8B
$5.2B
$5.4B
$5.5B
$6.4B
$5.9B
$6.0B
$6.1B
$7.2B
$6.0B
—
Zimmer Biomet Holdings, Inc. · ZBH
$1.7B
$1.8B
$1.7B
$1.8B
$1.7B
$1.8B
$1.8B
$1.9B
$1.8B
$1.9B
$1.9B
$1.9B
$1.8B
$2.0B
$1.9B
$2.1B
$2.0B
$2.2B
$2.1B
—
Revenue growth · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
—
—
—
10%
-4.7%
-12%
-18%
-11%
-2.6%
1.5%
2.2%
4.0%
4.9%
7.2%
4.0%
7.4%
6.9%
4.4%
7.8%
13%
Boston Scientific Corporation · BSX
—
—
—
5.4%
8.1%
3.7%
12%
11%
11%
15%
14%
14%
19%
22%
21%
23%
20%
16%
12%
—
DexCom, Inc. · DXCM
—
—
—
17%
18%
17%
18%
25%
27%
27%
24%
15%
2.0%
7.6%
12%
15%
22%
13%
15%
—
Edwards Lifesciences Corporation · EW
—
—
—
-0.2%
0.7%
1.4%
8.9%
-5.7%
-5.8%
-6.1%
-8.9%
5.6%
8.9%
9.5%
6.2%
12%
15%
13%
17%
—
GE HealthCare Technologies Inc. · GEHC
—
—
—
3.2%
6.3%
7.6%
8.4%
7.4%
5.4%
5.4%
-1.2%
0.5%
0.9%
2.2%
2.7%
3.5%
5.8%
7.1%
7.4%
—
Koninklijke Philips N.V. · PHG
—
—
—
-1.3%
3.7%
9.7%
6.4%
7.0%
3.7%
-6.6%
-0.7%
-0.2%
-2.1%
-0.4%
-1.0%
-2.8%
-1.7%
1.1%
-4.7%
—
Medtronic plc · MDT
—
—
—
—
-7.7%
-3.3%
-0.5%
5.6%
4.5%
5.3%
4.7%
0.5%
2.8%
5.3%
2.5%
3.9%
8.4%
6.6%
8.7%
9.9%
Penumbra, Inc. · PEN
—
—
—
13%
13%
8.3%
18%
25%
27%
29%
16%
15%
11%
11%
16%
13%
18%
22%
16%
—
Smith & Nephew plc · SNN
—
3.5%
—
—
0.0%
0.1%
—
—
5.2%
7.7%
—
—
—
6.0%
—
4.7%
—
7.4%
—
—
STERIS plc · STE
—
—
—
19%
0.3%
0.6%
14%
2.3%
3.1%
6.7%
2.5%
116%
115%
5.6%
4.4%
8.7%
9.9%
9.1%
7.2%
—
Stryker Corporation · SYK
—
—
—
4.6%
7.7%
11%
12%
11%
9.6%
12%
9.7%
8.5%
12%
11%
12%
11%
10%
11%
2.6%
—
Zimmer Biomet Holdings, Inc. · ZBH
—
—
—
1.1%
-0.9%
2.7%
10%
4.9%
5.0%
6.3%
3.2%
3.9%
4.0%
4.3%
1.1%
7.0%
9.7%
11%
9.3%
—
06 · compare level, then change
Operating Economics & Margin Trend
Edwards Lifesciences Corporation has the highest OPM among the 30 Medical Devices companies compared here, at 29%. DexCom, Inc. is next at 21.4%. LivaNova PLC has the highest Margin change at +109.8 percentage points, so level and change sit with different companies. 29 of 30 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Edwards Lifesciences Corporation leads opm at 29%; LivaNova PLC leads margin change at +109.8 percentage points.
LeaderEdwards Lifesciences Corporation · 29%
Gap35.5% versus #2 · DexCom, Inc.
Persistence3/8 recent comparable periods
Coverage29/30 companies · 549 observations
Investor read: Edwards Lifesciences Corporation sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
29/30 level · 29/30 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Edwards Lifesciences Corporation EW | 29% | +1.1 pp | Jun 2026 |
| DexCom, Inc. DXCM | 21% | +8.5 pp | Jun 2026 |
| Boston Scientific Corporation BSX | 21% | +1.4 pp | Jun 2026 |
| STERIS plc STE | 20% | +5.3 pp | Mar 2026 |
| Globus Medical, Inc. GMED | 20% | +3.6 pp | Mar 2026 |
| Medtronic plc MDT | 19% | +3.0 pp | Jun 2026 |
| Zimmer Biomet Holdings, Inc. ZBH | 18% | +2.6 pp | Mar 2026 |
| Insulet Corporation PODD | 16% | +0.4 pp | Mar 2026 |
| Stryker Corporation SYK | 16% | +1.2 pp | Jun 2026 |
| UFP Technologies, Inc. UFPT | 15% | −0.4 pp | Mar 2026 |
| Abbott Laboratories ABT | 13% | −5.0 pp | Jun 2026 |
| LivaNova PLC LIVN | 11% | +109.8 pp | Mar 2026 |
| Penumbra, Inc. PEN | 10% | −2.2 pp | Jun 2026 |
| GE HealthCare Technologies Inc. GEHC | 10% | −3.2 pp | Jun 2026 |
| TransMedics Group, Inc. TMDX | 7.6% | −11.5 pp | Mar 2026 |
| Integer Holdings Corporation ITGR | 7.2% | −5.3 pp | Jun 2026 |
| Koninklijke Philips N.V. PHG | 6.2% | +2.4 pp | Jun 2026 |
| Bio-Rad Laboratories, Inc. BIO-B | 5.8% | +1.8 pp | Mar 2026 |
| Bruker Corporation BRKR | 1.2% | −2.8 pp | Mar 2026 |
| Enovis Corporation ENOV | 1.1% | +9.5 pp | Jun 2026 |
| Inspire Medical Systems, Inc. INSP | -0.5% | +0.2 pp | Mar 2026 |
| Neogen Corporation NEOG | -1.6% | −4.0 pp | Jun 2026 |
| Axogen, Inc. AXGN | -4.6% | −1.2 pp | Jun 2026 |
| Haemonetics Corporation HAE | -6.6% | −28.2 pp | Mar 2026 |
| iRhythm Holdings, Inc. IRTC | -8.1% | +12.4 pp | Mar 2026 |
| Establishment Labs Holdings Inc. ESTA | -11% | +30.1 pp | Mar 2026 |
| Glaukos Corporation GKOS | -13% | +6.2 pp | Jun 2026 |
| NovoCure Limited NVCR | -39% | −14.3 pp | Jun 2026 |
| Butterfly Network, Inc. BFLY | -52% | +34.7 pp | Jun 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
23%
21%
25%
21%
17%
13%
16%
16%
16%
17%
14%
16%
18%
17%
16%
18%
18%
20%
12%
13%
Boston Scientific Corporation · BSX
13%
5.8%
15%
13%
11%
12%
16%
14%
20%
16%
18%
13%
17%
15%
20%
16%
21%
16%
21%
—
DexCom, Inc. · DXCM
18%
0.1%
6.6%
11%
19%
15%
6.4%
15%
21%
21%
11%
16%
15%
17%
13%
18%
20%
26%
21%
—
Edwards Lifesciences Corporation · EW
30%
28%
33%
33%
31%
33%
27%
20%
29%
27%
26%
27%
26%
23%
28%
27%
20%
9.6%
29%
—
GE HealthCare Technologies Inc. · GEHC
15%
16%
12%
14%
13%
16%
12%
12%
13%
13%
12%
13%
14%
15%
13%
13%
13%
15%
10%
—
Insulet Corporation · PODD
12%
16%
13%
-8.9%
0.9%
6.4%
7.7%
7.8%
13%
21%
13%
11%
16%
18%
16%
19%
17%
19%
16%
—
Koninklijke Philips N.V. · PHG
8.6%
3.3%
-4.6%
0.3%
-36%
3.2%
-14%
4.9%
5.0%
0.5%
-20%
18%
7.7%
3.9%
3.8%
9.2%
7.7%
11%
6.2%
—
Medtronic plc · MDT
11%
20%
21%
21%
15%
19%
18%
18%
17%
17%
18%
12%
16%
19%
20%
16%
17%
19%
16%
19%
Penumbra, Inc. · PEN
4.6%
-20%
-2.0%
-0.1%
2.5%
2.2%
3.3%
6.8%
4.7%
12%
4.3%
-27%
12%
14%
12%
12%
14%
15%
10%
—
STERIS plc · STE
9.7%
17%
7.6%
14%
-26%
16%
16%
17%
16%
17%
16%
7.2%
8.3%
18%
15%
8.8%
9.1%
18%
20%
—
Stryker Corporation · SYK
14%
17%
11%
17%
18%
16%
15%
19%
19%
22%
19%
19%
20%
9.0%
14%
19%
19%
25%
16%
—
Zimmer Biomet Holdings, Inc. · ZBH
14%
7.5%
12%
16%
15%
-1.6%
18%
18%
15%
18%
14%
18%
15%
19%
15%
14%
18%
6.9%
18%
—
Margin change · reported quarter history
Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
—
—
—
+7.5 pp
−6.3 pp
−7.8 pp
−9.0 pp
−5.6 pp
−0.8 pp
+4.5 pp
−1.6 pp
+0.6 pp
+1.3 pp
0.0 pp
+2.4 pp
+2.3 pp
+0.6 pp
+2.2 pp
−4.3 pp
−5.0 pp
Boston Scientific Corporation · BSX
—
—
—
+4.5 pp
−1.9 pp
+6.6 pp
+0.9 pp
+1.3 pp
+8.3 pp
+3.3 pp
+1.2 pp
−1.7 pp
−2.2 pp
−0.9 pp
+2.3 pp
+3.6 pp
+3.3 pp
+0.8 pp
+1.4 pp
—
DexCom, Inc. · DXCM
—
—
—
−5.9 pp
+1.0 pp
+15.3 pp
−0.2 pp
+3.6 pp
+1.9 pp
+5.6 pp
+4.6 pp
+1.0 pp
−5.8 pp
−4.0 pp
+1.9 pp
+2.7 pp
+4.8 pp
+8.6 pp
+8.5 pp
—
Edwards Lifesciences Corporation · EW
—
—
—
−6.0 pp
+0.7 pp
+5.0 pp
−6.1 pp
−13.1 pp
−1.1 pp
−5.8 pp
−0.4 pp
+6.5 pp
−3.5 pp
−4.8 pp
+1.7 pp
0.0 pp
−6.1 pp
−13.0 pp
+1.1 pp
—
GE HealthCare Technologies Inc. · GEHC
—
—
—
−2.2 pp
−1.9 pp
−0.1 pp
+0.2 pp
−2.3 pp
−0.4 pp
−2.5 pp
−0.3 pp
+0.8 pp
+1.1 pp
+1.9 pp
+1.6 pp
+0.5 pp
−1.2 pp
−0.6 pp
−3.2 pp
—
Insulet Corporation · PODD
—
—
—
−18.9 pp
−11.3 pp
−9.8 pp
−5.1 pp
+16.7 pp
+11.8 pp
+14.5 pp
+5.2 pp
+3.4 pp
+3.5 pp
−2.6 pp
+2.7 pp
+7.5 pp
+0.5 pp
+0.4 pp
+0.4 pp
—
Koninklijke Philips N.V. · PHG
—
—
—
−1.7 pp
−44.1 pp
−0.1 pp
−9.4 pp
+4.6 pp
+40.5 pp
−2.7 pp
−5.9 pp
+13.4 pp
+2.7 pp
+3.4 pp
+23.7 pp
−9.1 pp
0.0 pp
+6.7 pp
+2.4 pp
—
Medtronic plc · MDT
—
—
—
—
+4.5 pp
−1.4 pp
−3.4 pp
−2.4 pp
+1.2 pp
−1.7 pp
+0.3 pp
−6.0 pp
−0.4 pp
+2.2 pp
+1.6 pp
+3.8 pp
+0.7 pp
−0.2 pp
−3.7 pp
+3.0 pp
Penumbra, Inc. · PEN
—
—
—
−5.7 pp
−2.1 pp
+21.8 pp
+5.3 pp
+6.9 pp
+2.2 pp
+10.1 pp
+1.0 pp
−33.8 pp
+7.0 pp
+1.3 pp
+8.1 pp
+39.0 pp
+2.1 pp
+1.8 pp
−2.2 pp
—
STERIS plc · STE
—
—
—
+12.2 pp
−35.2 pp
−1.1 pp
+8.7 pp
+3.0 pp
+41.0 pp
+1.7 pp
−0.8 pp
−9.5 pp
−7.2 pp
+0.5 pp
−0.9 pp
+1.6 pp
+0.8 pp
+0.4 pp
+5.3 pp
—
Stryker Corporation · SYK
—
—
—
+0.2 pp
+4.2 pp
−1.8 pp
+4.9 pp
+2.1 pp
+1.0 pp
+6.0 pp
+3.1 pp
+0.1 pp
+0.7 pp
−12.6 pp
−4.2 pp
−0.9 pp
−1.0 pp
+16.2 pp
+1.2 pp
—
Zimmer Biomet Holdings, Inc. · ZBH
—
—
—
+3.1 pp
+0.3 pp
−9.1 pp
+6.0 pp
+1.8 pp
+0.5 pp
+19.9 pp
−3.8 pp
+0.5 pp
+0.1 pp
+0.9 pp
+1.2 pp
−3.7 pp
+2.3 pp
−12.3 pp
+2.6 pp
—
07 · compare level, then change
Profit Scale & Acceleration
Abbott Laboratories has the highest Net profit among the 30 Medical Devices companies compared here, at $5,425 million. Medtronic plc is next at $4,837 million. Globus Medical, Inc. has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Abbott Laboratories leads with $5,425 million of TTM profit, 12.2% above Medtronic plc. Globus Medical, Inc. shows ≥100% on the scoring scale (215.6% uncapped) growth from a $587 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderAbbott Laboratories · $5,425 million
Gap12.2% versus #2 · Medtronic plc
Persistence4/8 recent comparable periods
Coverage15/30 companies · 559 observations
Investor read: Abbott Laboratories sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
Net profit · company comparison
15/30 level · 11/30 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Boston Scientific Corporation BSX | $1.3B | 99% | Jun 2026 |
| Medtronic plc MDT | $1.3B | 19% | Jun 2026 |
| Abbott Laboratories ABT | $928M | -48% | Jun 2026 |
| Stryker Corporation SYK | $745M | 14% | Jun 2026 |
| GE HealthCare Technologies Inc. GEHC | $411M | -30% | Jun 2026 |
| Edwards Lifesciences Corporation EW | $381M | 4.7% | Jun 2026 |
| Smith & Nephew plc SNN | $332M | 68% | Dec 2025 |
| Zimmer Biomet Holdings, Inc. ZBH | $238M | 30% | Mar 2026 |
| STERIS plc STE | $220M | 51% | Mar 2026 |
| DexCom, Inc. DXCM | $200M | 90% | Jun 2026 |
| Koninklijke Philips N.V. PHG | $146M | 103% | Jun 2026 |
| Globus Medical, Inc. GMED | $124M | 65% | Mar 2026 |
| Insulet Corporation PODD | $91M | 160% | Mar 2026 |
| Penumbra, Inc. PEN | $33M | -15% | Jun 2026 |
| LivaNova PLC LIVN | $23M | 546% | Mar 2026 |
| Integer Holdings Corporation ITGR | $17M | -54% | Jun 2026 |
| UFP Technologies, Inc. UFPT | $17M | 0.0% | Mar 2026 |
| Bruker Corporation BRKR | $16M | -5.9% | Mar 2026 |
| TransMedics Group, Inc. TMDX | $7M | -73% | Mar 2026 |
| Inspire Medical Systems, Inc. INSP | $-11M | -467% | Mar 2026 |
| Establishment Labs Holdings Inc. ESTA | $-13M | — | Mar 2026 |
| Butterfly Network, Inc. BFLY | $-13M | — | Jun 2026 |
| iRhythm Holdings, Inc. IRTC | $-14M | — | Mar 2026 |
| Enovis Corporation ENOV | $-15M | -117% | Jun 2026 |
| Neogen Corporation NEOG | $-17M | -750% | Jun 2026 |
| Glaukos Corporation GKOS | $-20M | -800% | Jun 2026 |
| Haemonetics Corporation HAE | $-20M | -134% | Mar 2026 |
| Axogen, Inc. AXGN | $-20M | -1,400% | Jun 2026 |
| NovoCure Limited NVCR | $-71M | — | Jun 2026 |
| Bio-Rad Laboratories, Inc. BIO-B | $-527M | -923% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
$2.1B
$2.0B
$2.4B
$2.0B
$1.4B
$1.0B
$1.3B
$1.4B
$1.4B
$1.6B
$1.2B
$1.3B
$1.6B
$9.2B
$1.3B
$1.8B
$1.6B
$1.8B
$1.1B
$928M
Boston Scientific Corporation · BSX
$419M
$93M
$111M
$260M
$188M
$141M
$313M
$270M
$505M
$504M
$493M
$322M
$468M
$562M
$672M
$795M
$755M
$670M
$1.3B
—
DexCom, Inc. · DXCM
$87M
$-5M
$97M
$51M
$101M
$92M
$49M
$116M
$121M
$256M
$146M
$144M
$135M
$152M
$105M
$180M
$284M
$267M
$200M
—
Edwards Lifesciences Corporation · EW
$340M
$335M
$374M
$406M
$344M
$387M
$341M
$254M
$335M
$333M
$325M
$364M
$362M
$345M
$364M
$336M
$292M
$64M
$381M
—
GE HealthCare Technologies Inc. · GEHC
$527M
$576M
$402M
$498M
$493M
$573M
$383M
$433M
$382M
$416M
$388M
$435M
$490M
$738M
$588M
$500M
$464M
$602M
$411M
—
Koninklijke Philips N.V. · PHG
$3.0B
$151M
$-151M
$-20M
$-1.3B
$-105M
$-665M
$74M
$90M
$38M
$-998M
$452M
$181M
$-333M
$72M
$240M
$187M
$397M
$146M
—
Medtronic plc · MDT
$769M
$1.3B
$1.5B
$1.5B
$931M
$435M
$1.2B
$1.2B
$797M
$911M
$1.3B
$660M
$1.0B
$1.3B
$1.3B
$1.1B
$1.0B
$1.4B
$1.2B
$1.3B
Penumbra, Inc. · PEN
$8M
$-25M
$0M
$-4M
$-2M
$4M
$9M
$19M
$9M
$54M
$11M
$-60M
$30M
$34M
$39M
$45M
$46M
$47M
$33M
—
Smith & Nephew plc · SNN
$205M
$319M
—
—
$177M
$46M
—
—
$172M
$91M
—
$214M
—
$198M
—
$293M
—
$332M
—
—
STERIS plc · STE
$70M
$143M
$52M
$111M
$-315M
$123M
$187M
$124M
$116M
$141M
$-1M
$146M
$151M
$173M
$146M
$178M
$193M
$194M
$220M
—
Stryker Corporation · SYK
$438M
$662M
$323M
$656M
$816M
$563M
$592M
$738M
$692M
$1.1B
$788M
$825M
$834M
$546M
$654M
$884M
$859M
$849M
$745M
—
Zimmer Biomet Holdings, Inc. · ZBH
$162M
$-55M
$73M
$154M
$194M
$-130M
$233M
$210M
$163M
$420M
$173M
$243M
$249M
$240M
$183M
$153M
$231M
$138M
$238M
—
Profit growth · reported quarter history
Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
—
—
—
70%
-32%
-48%
-46%
-32%
0.1%
54%
-7.1%
-5.3%
15%
479%
8.2%
37%
-0.1%
-81%
-19%
-48%
Boston Scientific Corporation · BSX
—
—
—
40%
-55%
52%
182%
3.9%
169%
257%
58%
19%
-7.3%
12%
36%
147%
61%
19%
99%
—
DexCom, Inc. · DXCM
—
—
—
-35%
16%
—
-49%
127%
20%
178%
198%
24%
12%
-41%
-28%
25%
110%
76%
90%
—
Edwards Lifesciences Corporation · EW
—
—
—
-17%
1.2%
16%
-8.8%
-37%
-2.6%
-14%
-4.7%
43%
8.1%
3.6%
12%
-7.7%
-19%
-81%
4.7%
—
GE HealthCare Technologies Inc. · GEHC
—
—
—
-16%
-6.5%
-0.5%
-4.7%
-13%
-23%
-27%
1.3%
0.5%
28%
77%
52%
15%
-5.3%
-18%
-30%
—
Koninklijke Philips N.V. · PHG
—
—
—
-113%
-145%
-170%
—
—
—
—
—
511%
101%
-976%
—
-47%
3.3%
—
103%
—
Medtronic plc · MDT
—
—
—
—
21%
-67%
-17%
-20%
-14%
109%
8.8%
-44%
32%
40%
-2.5%
61%
-0.2%
8.1%
-12%
19%
Penumbra, Inc. · PEN
—
—
—
-150%
-125%
—
—
—
—
1,250%
22%
-416%
233%
-37%
255%
—
53%
38%
-15%
—
Smith & Nephew plc · SNN
—
-8.3%
—
—
-14%
-86%
—
—
-2.8%
98%
—
—
—
118%
—
37%
—
68%
—
—
STERIS plc · STE
—
—
—
—
-550%
-14%
260%
12%
—
15%
-101%
18%
30%
23%
—
22%
28%
12%
51%
—
Stryker Corporation · SYK
—
—
—
11%
86%
-15%
83%
13%
-15%
103%
33%
12%
21%
-52%
-17%
7.2%
3.0%
55%
14%
—
Zimmer Biomet Holdings, Inc. · ZBH
—
—
—
6.2%
20%
—
219%
36%
-16%
—
-26%
16%
53%
-43%
5.8%
-37%
-7.2%
-43%
30%
—
08 · compare level, then change
Return On Capital Employed
Edwards Lifesciences Corporation has the highest ROCE among the 30 Medical Devices companies compared here, at 8.5%. DexCom, Inc. is next at 7.8%. LivaNova PLC has the highest ROCE change at +18.1 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Edwards Lifesciences Corporation leads ROCE at 8.5%, 0.7 percentage points above DexCom, Inc.. LivaNova PLC has the strongest latest improvement at +18.1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderEdwards Lifesciences Corporation · 8.5%
Gap9% versus #2 · DexCom, Inc.
Persistence2/8 recent comparable periods
Coverage30/30 companies · 571 observations
Investor read: Edwards Lifesciences Corporation sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
30/30 level · 30/30 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Edwards Lifesciences Corporation EW | 8.5% | +4.6 pp | Jun 2026 |
| DexCom, Inc. DXCM | 7.8% | +3.1 pp | Jun 2026 |
| Boston Scientific Corporation BSX | 6.5% | +4.1 pp | Jun 2026 |
| Insulet Corporation PODD | 4.6% | +1.2 pp | Mar 2026 |
| Stryker Corporation SYK | 4.1% | +1.0 pp | Jun 2026 |
| UFP Technologies, Inc. UFPT | 4.0% | −1.0 pp | Mar 2026 |
| STERIS plc STE | 3.4% | +1.2 pp | Mar 2026 |
| Koninklijke Philips N.V. PHG | 3.2% | +1.2 pp | Jun 2026 |
| Globus Medical, Inc. GMED | 3.2% | +0.9 pp | Mar 2026 |
| GE HealthCare Technologies Inc. GEHC | 2.7% | 0.0 pp | Jun 2026 |
| Penumbra, Inc. PEN | 2.5% | −0.3 pp | Jun 2026 |
| Medtronic plc MDT | 2.3% | +0.5 pp | Jun 2026 |
| LivaNova PLC LIVN | 2.3% | +18.1 pp | Mar 2026 |
| Abbott Laboratories ABT | 2.1% | −1.1 pp | Jun 2026 |
| Smith & Nephew plc SNN | 2.1% | +0.1 pp | Dec 2025 |
| Zimmer Biomet Holdings, Inc. ZBH | 1.9% | +0.4 pp | Mar 2026 |
| TransMedics Group, Inc. TMDX | 1.3% | −2.5 pp | Mar 2026 |
| Integer Holdings Corporation ITGR | 1.0% | −1.0 pp | Jun 2026 |
| Bio-Rad Laboratories, Inc. BIO-B | 0.4% | +0.2 pp | Mar 2026 |
| Bruker Corporation BRKR | 0.2% | −0.6 pp | Mar 2026 |
| Enovis Corporation ENOV | 0.2% | +1.2 pp | Jun 2026 |
| Neogen Corporation NEOG | 0.1% | +16.0 pp | Jun 2026 |
| Inspire Medical Systems, Inc. INSP | -0.2% | 0.0 pp | Mar 2026 |
| Axogen, Inc. AXGN | -0.9% | −1.9 pp | Jun 2026 |
| Haemonetics Corporation HAE | -1.2% | −5.0 pp | Mar 2026 |
| iRhythm Holdings, Inc. IRTC | -1.9% | +2.1 pp | Mar 2026 |
| Glaukos Corporation GKOS | -2.0% | +0.6 pp | Jun 2026 |
| NovoCure Limited NVCR | -2.0% | +3.1 pp | Jun 2026 |
| Establishment Labs Holdings Inc. ESTA | -2.4% | +4.1 pp | Mar 2026 |
| Butterfly Network, Inc. BFLY | -5.5% | +0.9 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
4.3%
3.9%
4.8%
3.9%
2.9%
2.2%
2.5%
2.6%
2.8%
3.0%
2.4%
2.8%
3.1%
3.0%
2.7%
3.2%
3.2%
3.3%
1.7%
2.1%
Boston Scientific Corporation · BSX
1.4%
0.7%
1.7%
1.5%
1.3%
1.4%
1.9%
1.8%
2.4%
2.0%
2.2%
1.7%
2.4%
2.1%
2.8%
2.4%
3.0%
2.3%
2.9%
6.5%
DexCom, Inc. · DXCM
3.2%
0.0%
1.0%
1.9%
3.7%
3.2%
1.2%
2.8%
4.6%
5.3%
2.4%
3.2%
3.2%
4.6%
3.1%
4.7%
5.5%
8.3%
6.3%
7.8%
Edwards Lifesciences Corporation · EW
5.9%
5.4%
6.3%
6.5%
5.4%
6.1%
5.2%
3.4%
4.6%
4.5%
4.3%
4.4%
3.7%
3.2%
3.9%
3.9%
2.7%
1.3%
4.1%
8.5%
GE HealthCare Technologies Inc. · GEHC
3.5%
3.9%
—
—
3.1%
3.9%
4.6%
4.6%
2.8%
3.1%
2.3%
2.5%
2.7%
3.4%
2.7%
2.7%
2.5%
3.2%
2.0%
2.7%
Koninklijke Philips N.V. · PHG
1.6%
0.7%
-0.8%
0.0%
-6.6%
0.7%
-2.6%
1.0%
1.0%
0.1%
-3.9%
3.9%
1.6%
0.9%
0.7%
2.0%
1.6%
2.7%
1.2%
3.2%
Medtronic plc · MDT
—
1.9%
2.0%
2.0%
1.4%
1.7%
1.7%
2.0%
1.6%
1.7%
1.8%
1.3%
1.6%
2.0%
2.1%
1.8%
1.8%
2.1%
1.8%
2.3%
Penumbra, Inc. · PEN
1.1%
-4.4%
-0.4%
0.0%
0.5%
0.4%
0.7%
1.4%
1.0%
2.7%
0.9%
-6.1%
2.7%
3.1%
2.8%
2.8%
3.4%
3.9%
2.4%
2.5%
Smith & Nephew plc · SNN
1.4%
29%
—
1.4%
1.4%
17%
—
1.7%
1.7%
1.8%
1.9%
1.9%
2.0%
2.0%
2.4%
2.4%
2.1%
2.1%
—
—
STERIS plc · STE
1.5%
2.4%
1.1%
1.5%
-3.0%
1.8%
2.2%
2.0%
1.9%
2.1%
2.4%
1.9%
2.2%
2.5%
2.2%
2.6%
2.8%
2.9%
3.4%
—
Stryker Corporation · SYK
2.0%
2.8%
1.5%
2.5%
2.6%
2.7%
2.3%
3.1%
3.0%
4.0%
3.1%
3.3%
3.3%
1.7%
2.4%
3.1%
3.0%
4.8%
2.4%
4.1%
Zimmer Biomet Holdings, Inc. · ZBH
1.1%
0.6%
1.0%
1.4%
1.2%
-0.1%
1.7%
1.7%
1.4%
1.9%
1.4%
1.9%
1.5%
2.1%
1.5%
1.6%
1.8%
0.8%
1.9%
—
ROCE change · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
—
—
—
—
−1.4 pp
−1.7 pp
−2.3 pp
−1.3 pp
−0.1 pp
+0.8 pp
−0.1 pp
+0.2 pp
+0.3 pp
0.0 pp
+0.3 pp
+0.4 pp
+0.1 pp
+0.3 pp
−1.0 pp
−1.1 pp
Boston Scientific Corporation · BSX
—
—
—
—
−0.1 pp
+0.7 pp
+0.2 pp
+0.3 pp
+1.1 pp
+0.6 pp
+0.3 pp
−0.1 pp
0.0 pp
+0.1 pp
+0.6 pp
+0.7 pp
+0.6 pp
+0.2 pp
+0.1 pp
+4.1 pp
DexCom, Inc. · DXCM
—
—
—
—
+0.5 pp
+3.2 pp
+0.2 pp
+0.9 pp
+0.9 pp
+2.1 pp
+1.2 pp
+0.4 pp
−1.4 pp
−0.7 pp
+0.7 pp
+1.5 pp
+2.3 pp
+3.7 pp
+3.2 pp
+3.1 pp
Edwards Lifesciences Corporation · EW
—
—
—
—
−0.5 pp
+0.7 pp
−1.1 pp
−3.1 pp
−0.8 pp
−1.6 pp
−0.9 pp
+1.0 pp
−0.9 pp
−1.3 pp
−0.4 pp
−0.5 pp
−1.0 pp
−1.9 pp
+0.2 pp
+4.6 pp
GE HealthCare Technologies Inc. · GEHC
—
—
—
—
−0.4 pp
0.0 pp
—
—
−0.3 pp
−0.8 pp
−2.3 pp
−2.1 pp
−0.1 pp
+0.3 pp
+0.4 pp
+0.2 pp
−0.2 pp
−0.2 pp
−0.7 pp
0.0 pp
Koninklijke Philips N.V. · PHG
—
—
—
—
−8.2 pp
0.0 pp
−1.8 pp
+1.0 pp
+7.6 pp
−0.6 pp
−1.3 pp
+2.9 pp
+0.6 pp
+0.8 pp
+4.6 pp
−1.9 pp
0.0 pp
+1.8 pp
+0.5 pp
+1.2 pp
Medtronic plc · MDT
—
—
—
—
—
−0.2 pp
−0.3 pp
0.0 pp
+0.2 pp
0.0 pp
+0.1 pp
−0.7 pp
0.0 pp
+0.3 pp
+0.3 pp
+0.5 pp
+0.2 pp
+0.1 pp
−0.3 pp
+0.5 pp
Penumbra, Inc. · PEN
—
—
—
—
−0.6 pp
+4.8 pp
+1.1 pp
+1.4 pp
+0.5 pp
+2.3 pp
+0.2 pp
−7.5 pp
+1.7 pp
+0.4 pp
+1.9 pp
+8.9 pp
+0.7 pp
+0.8 pp
−0.4 pp
−0.3 pp
Smith & Nephew plc · SNN
—
—
—
—
0.0 pp
−12.4 pp
—
+0.3 pp
+0.3 pp
−14.8 pp
—
+0.2 pp
+0.3 pp
+0.2 pp
+0.5 pp
+0.5 pp
+0.1 pp
+0.1 pp
—
—
STERIS plc · STE
—
—
—
—
−4.5 pp
−0.6 pp
+1.1 pp
+0.5 pp
+4.9 pp
+0.3 pp
+0.2 pp
−0.1 pp
+0.3 pp
+0.4 pp
−0.2 pp
+0.7 pp
+0.6 pp
+0.4 pp
+1.2 pp
—
Stryker Corporation · SYK
—
—
—
—
+0.6 pp
−0.1 pp
+0.8 pp
+0.6 pp
+0.4 pp
+1.3 pp
+0.8 pp
+0.2 pp
+0.3 pp
−2.3 pp
−0.7 pp
−0.2 pp
−0.3 pp
+3.1 pp
0.0 pp
+1.0 pp
Zimmer Biomet Holdings, Inc. · ZBH
—
—
—
—
+0.1 pp
−0.7 pp
+0.7 pp
+0.3 pp
+0.2 pp
+2.0 pp
−0.3 pp
+0.2 pp
+0.1 pp
+0.2 pp
+0.1 pp
−0.3 pp
+0.3 pp
−1.3 pp
+0.4 pp
—
09 · compare level, then change
Valuation Against Growth & Quality
Haemonetics Corporation has the lowest PEG among the 30 Medical Devices companies compared here, at 0.52×. Globus Medical, Inc. is next at 0.85×. Inspire Medical Systems, Inc. has the lowest P/E at 11.5×, so level and change sit with different companies. 8 of 30 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Haemonetics Corporation has the lowest comparable PEG at 0.52×, 38.8% below Globus Medical, Inc.. Only 8 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderHaemonetics Corporation · 0.52×
Gap38.8% versus #2 · Globus Medical, Inc.
Persistence0/8 recent comparable periods
Coverage8/30 companies · 69 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
P/Elowest P/E
Valuation · company comparison
8/30 level · 24/30 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Edwards Lifesciences Corporation EW | 5.1 | 52.0 | Jun 2026 |
| GE HealthCare Technologies Inc. GEHC | 3.4 | 14.7 | Jun 2026 |
| Medtronic plc MDT | 3.1 | 22.3 | Jun 2026 |
| UFP Technologies, Inc. UFPT | 2.9 | 22.0 | Mar 2026 |
| Abbott Laboratories ABT | 2.3 | 29.4 | Jun 2026 |
| Bruker Corporation BRKR | 2.3 | 79.2 | Mar 2026 |
| Stryker Corporation SYK | 2.3 | 32.6 | Jun 2026 |
| Integer Holdings Corporation ITGR | 1.5 | 21.6 | Jun 2026 |
| Inspire Medical Systems, Inc. INSP | 1.4 | 11.5 | Mar 2026 |
| STERIS plc STE | 1.0 | 27.9 | Mar 2026 |
| Boston Scientific Corporation BSX | 0.9 | 17.3 | Jun 2026 |
| Globus Medical, Inc. GMED | 0.9 | 20.0 | Mar 2026 |
| DexCom, Inc. DXCM | 0.7 | 26.6 | Jun 2026 |
| Haemonetics Corporation HAE | 0.5 | 26.4 | Mar 2026 |
| Koninklijke Philips N.V. PHG | — | 20.5 | Jun 2026 |
| Zimmer Biomet Holdings, Inc. ZBH | — | 23.5 | Mar 2026 |
| Penumbra, Inc. PEN | — | 134.4 | Jun 2026 |
| Smith & Nephew plc SNN | — | 22.9 | Dec 2025 |
| Insulet Corporation PODD | — | 48.8 | Mar 2026 |
| Bio-Rad Laboratories, Inc. BIO-B | — | 45.9 | Mar 2026 |
| LivaNova PLC LIVN | — | 32.6 | Mar 2026 |
| TransMedics Group, Inc. TMDX | — | 22.6 | Mar 2026 |
| Neogen Corporation NEOG | — | 1,719.0 | Jun 2026 |
| Enovis Corporation ENOV | — | 58.3 | Jun 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
—
—
—
—
—
—
—
—
—
—
—
2.9
2.3
—
—
—
—
—
—
—
Boston Scientific Corporation · BSX
—
—
—
—
—
—
7.5
—
—
—
—
—
1.5
4.3
4.9
1.8
1.0
0.9
—
—
Bruker Corporation · BRKR
—
—
—
—
—
—
2.9
1.8
1.5
0.5
1.1
2.3
—
—
—
—
—
—
—
—
DexCom, Inc. · DXCM
—
—
—
—
—
—
12.9
2.7
1.8
—
—
—
—
6.0
—
—
4.8
0.7
—
—
Edwards Lifesciences Corporation · EW
—
—
—
—
—
—
—
—
—
—
—
5.1
—
—
—
—
—
—
—
—
GE HealthCare Technologies Inc. · GEHC
—
—
—
—
—
—
—
—
—
—
—
—
3.1
0.4
0.4
0.4
0.5
3.4
—
—
Globus Medical, Inc. · GMED
—
—
—
—
—
—
0.6
0.9
—
—
—
—
—
—
—
—
—
—
—
—
Haemonetics Corporation · HAE
—
—
—
—
—
—
—
—
—
—
—
—
—
—
0.5
0.8
0.3
0.5
—
—
Integer Holdings Corporation · ITGR
—
—
—
—
—
—
—
—
—
—
0.7
1.0
1.0
1.5
—
—
—
—
—
—
Medtronic plc · MDT
—
—
—
—
—
—
—
—
—
—
—
—
2.9
4.3
—
0.7
1.1
1.9
3.1
—
STERIS plc · STE
—
—
—
—
—
—
—
—
—
—
—
—
5.7
3.4
2.4
2.2
2.1
2.4
1.0
—
Stryker Corporation · SYK
—
—
—
—
—
—
1.4
1.4
—
1.1
1.5
1.4
1.0
—
—
—
—
5.1
2.3
—
P/E · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Abbott Laboratories · ABT
29.3
35.7
27.5
22.7
21.8
28.1
31.6
38.3
33.9
33.8
35.4
32.8
34.7
14.8
17.2
17.0
16.8
33.7
28.8
29.4
Boston Scientific Corporation · BSX
56.4
59.0
83.6
64.3
92.2
102.8
84.8
90.2
64.4
54.0
57.6
62.6
69.3
71.5
73.6
63.9
52.2
49.2
26.3
17.3
DexCom, Inc. · DXCM
97.0
253.3
206.3
135.5
138.9
138.1
166.0
149.4
102.5
95.5
89.5
70.0
40.1
54.8
51.0
60.6
37.4
31.8
26.8
26.6
Edwards Lifesciences Corporation · EW
48.2
54.4
48.3
41.2
35.6
30.6
34.3
41.7
29.6
33.2
41.2
38.0
9.5
10.6
10.4
11.3
33.5
46.6
42.6
52.0
GE HealthCare Technologies Inc. · GEHC
—
—
—
—
—
13.8
21.8
22.5
20.3
25.5
26.6
22.7
25.8
18.0
17.0
15.2
15.5
18.0
17.0
14.7
Koninklijke Philips N.V. · PHG
9.4
8.9
8.1
6.9
—
—
—
—
—
—
—
—
—
—
60.2
119.7
136.6
24.8
23.4
20.5
Medtronic plc · MDT
—
34.5
28.4
28.0
23.9
27.0
27.2
32.3
32.6
22.6
27.6
28.9
26.6
27.7
27.4
23.3
25.6
25.3
28.1
22.3
Penumbra, Inc. · PEN
292.9
2,052.3
—
—
—
—
1,741.8
465.0
234.9
108.4
94.2
529.3
225.9
—
—
210.4
154.5
—
125.3
134.4
Smith & Nephew plc · SNN
35.0
29.0
—
27.8
24.7
52.7
—
55.3
64.5
45.3
39.0
35.5
38.0
26.2
27.3
27.1
28.5
22.9
—
—
STERIS plc · STE
73.0
84.2
97.5
55.3
—
—
178.8
184.4
39.7
38.5
59.0
39.3
40.9
32.8
36.6
36.8
35.6
35.4
27.9
—
Stryker Corporation · SYK
53.1
51.3
50.8
36.6
31.5
39.6
41.6
43.1
40.5
36.3
40.7
37.8
38.6
46.4
50.3
52.4
48.6
41.8
38.0
32.6
Zimmer Biomet Holdings, Inc. · ZBH
36.5
64.5
124.2
96.4
79.2
115.9
60.4
60.4
49.7
24.9
28.6
22.6
20.5
23.8
25.0
22.2
24.4
25.3
23.5
—
10 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Medical Devices comparison names 5 specific ways its own evidence can mislead, all listed below. 1 of the 30 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
11 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 30 Medical Devices companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-04. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-04 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
12 · questions investors ask, short speakable answers
Medical Devices company comparison FAQs
These 22 answers restate the Medical Devices comparison above in question form. Every one is computed from the same 30 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-04. Nothing here is estimated, and none of it is a recommendation.
Is the Medical Devices sector outperforming S&P 500?
Medical Devices has outperformed S&P 500 by 12.5% over 52 weeks and 17.9% over 13 weeks. 13 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 11 of 29 beat the sector itself.
Which Medical Devices company is largest by revenue?
Abbott Laboratories leads with revenue of $46,585 million, based on 15 of 30 comparable companies through Jun 2026.
Which Medical Devices company is growing fastest?
Establishment Labs Holdings Inc. has the fastest current revenue growth at 35.3%, across 15 of 30 comparable companies.
Which Medical Devices company has the strongest 4-Factor Sector Score?
DexCom, Inc. ranks first at 66.1/100 with 57.8% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Medical Devices company has the lowest comparable PEG?
Haemonetics Corporation has the lowest comparable PEG at 0.52, among 8 of 30 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Medical Devices comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Which Medical Devices company is the biggest?
Abbott Laboratories is the largest, with trailing-twelve-month revenue of $46,585 million, ahead of Medtronic plc at $36,363 million. That covers 15 of 30 companies with comparable reporting through Jun 2026.
Which Medical Devices company has the best profit margins?
Edwards Lifesciences Corporation has the highest operating margin at 29%, from 29 of 30 comparable companies. LivaNova PLC shows the biggest recent improvement, at +109.8 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Medical Devices company makes the most profit?
Abbott Laboratories earns the most, at $5,425 million of trailing-twelve-month net profit, from 15 of 30 comparable companies. Globus Medical, Inc. has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Medical Devices company earns the highest return on capital?
Edwards Lifesciences Corporation leads on return on capital employed at 8.5%, across 30 of 30 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Medical Devices stock is the cheapest?
On PEG — where a LOWER number is cheaper — Haemonetics Corporation screens cheapest at 0.52×. Only 8 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Medical Devices sector beating the market?
Medical Devices has outperformed S&P 500 by 12.5% over the last 52 weeks and 17.9% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 13 of 29 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Medical Devices stock has the strongest price momentum?
Butterfly Network, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Medical Devices company scores highest for research priority?
DexCom, Inc. scores 66.1 out of 100 with 57.8% evidence confidence, from 22.9 points on growth and earnings, 16.8 on capital efficiency, 9.9 on valuation and 16.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Medical Devices companies does this comparison cover, and over what period?
It compares 30 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Medical Devices sector?
The 30 Medical Devices companies on this page carry $788,749 million of combined market value. Abbott Laboratories is the largest at $182,486 million, about 23% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-04.
What is the Medical Devices sector's P/E ratio?
The median price-to-earnings ratio across the 30 Medical Devices companies on this page is 26.6×, measured on the 24 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-04.
How is the Medical Devices sector performing?
13 of the 29 covered Medical Devices companies are beating S&P 500 on Mansfield relative strength. The sector itself is 12.5% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-04.
How many Medical Devices stocks are listed in the US?
This comparison covers 30 listed Medical Devices companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.